Replacement therapy in the mucopolysaccharidoses

MICHAEL F. DEAN

From the Division of Biochemistry, Kennedy Institute of Rheumatology, London

Glycosaminoglycans (GAG), one of the major constituents of connective tissues, are long, unbranched polysaccharides that can contain as many as 100 sugar residues per chain (Muir and Hardingham, 1975). They are normally present not as free chains but grouped together in large numbers with each chain covalently linked at one end (the reducing terminus) to a central protein core, the whole forming a single proteoglycan molecule. Each GAG chain is composed of alternating residues of uronic acid and hexosamine, except for an atypical trisaccharide linkage region at the reducing terminus. In keratan sulphate, however, uronic acid is replaced by galactose. The hexosamine residues (D-glucosamine or D-galactosamine) are usually-N-acetylated and O-sulphated, but N-sulphate groups are often present in heparin and heparan sulphate. The uronic acid residues are either D-glucuronic or L-iduronic, with the latter often being sulphated.

Catabolism of GAG is a complicated process. Complete chains can be degraded into smaller fragments by the action of endoglycosidases acting on susceptible internal linkages such as, for example, testicular hyaluronidase (EC 3.2.1.35), which can degrade chondroitin sulphates and hyaluronic acid to produce tetra- and hexasaccharides and has a similar but more limited action on dermalan sulphate. Similarly, an endoglycosidase found in human platelets (Wasteson et al., 1970) can degrade heparan sulphate to produce a range of GAG fragments, the smallest equivalent in size to a hexasaccharide. Complete catabolism to release constituent monosaccharides and inorganic sulphate then requires the concerted action of a number of different lysosomal exoglycosidase and sulphatase enzymes that remove one sugar residue or sulphate group at a time from the non-reducing terminal end of the remaining partially degraded GAG chains. A deficiency in any one of these enzymes interrupts the sequence, leading to intracellular accumulation of partially degraded GAG as lysosomal storage products and their excretion in large amounts in urine. To date seven such enzyme deficiencies have been described (Table 1). They give rise to the group of inherited diseases of connective tissue known as the mucopolysaccharidoses.

Cultured fibroblasts and corrective factors

The discovery of the nature of the defect in each type of mucopolysaccharidosis arose mainly from the work of Neufeld and her collaborators (Fratantoni et al., 1968, 1969), who showed that when skin fibroblasts from different types of mucopolysaccharidosis were grown together in culture they were able to correct abnormal accumulation of GAG (measured as precipitable 35SO4) in each others' cells. They further demonstrated that this correction could be achieved simply by adding medium in which cells of a different genotype had been cultured previously, due to the release of soluble 'corrective factors'. These 'corrective factors' were subsequently identified as lysosomal enzymes (Bach et al., 1972; Bach et al., 1973; Kresse, 1973; O'Brien, 1972; Hall et al., 1973; Matalon et al., 1974; Fluharty et al., 1974; Gniot-Szulzycka and Donnelly, 1976; Singh et al., 1976). Because normal fibroblasts produce all these lysosomal enzymes they are able to correct every type of mucopolysaccharidosis. They are released into the extracellular environment from whence they are taken up by active endocytosis into pinocytotic vesicles (von Figura and Kresse, 1974; Brot et al., 1974; Hickman et al., 1974) which can then fuse with lysosomes containing partially degraded GAG. Lysosomal deficiency diseases like the mucopolysaccharidoses are thus ideally suited to replacement therapy with an external source of active enzymes.

Replacement therapy by plasma infusion

The discovery that the mucopolysaccharidoses were a related group of lysosomal enzyme deficiency diseases prompted a number of attempts at replacement therapy, with normal plasma as the most readily available source of active enzymes. The first attempt was made by Di Ferrante et al. (1971), who infused about 1 l of plasma into one child with Hunter's disease and two with Hunter's disease. This was followed by a transfusion of leucocytes suspended in a small volume of autologous plasma into another patient with Hunter's disease (Knudson et al., 1971). These transfusions induced increased breakdown and excretion of dermatan and heparan sulphates, while
clinical changes included a reduction in hyperactivity, an improvement in the patients' poorly vascularised extremities, and improved joint mobility. Normal plasma equivalent to 3.5 l of blood was infused into three patients with Sanfilippo's disease by Dean et al. (1973) and one with Hunter's disease (Dean et al., 1975a). The changes seen in these cases after infusion included an increased excretion of uronic acid (see Fig. 1) and an increase in the relative proportions of lower molecular weight oligosaccharides separated by chromatography on Sephadex G-25 (Fig. 2).

These changes were consistent with those expected from increased breakdown and mobilisation of excreted GAG and were not seen when one of the patients with Sanfilippo's disease was infused with an equivalent volume of iso-osmotic dextran solution one year later (Dean et al., 1975b), indicating that the increased output of degraded GAG was a specific phenomenon, attributable to lysosomal enzymes in plasma. Yatziv et al. (1975) also noted transient increases in urinary oligosaccharides derived from heparan sulphate after giving fresh plasma to two siblings with Hunter's disease. Accompanying clinical changes included a decrease in the size of liver and spleen, improved joint mobility, accelerated growth, and a decrease in the incidence of respiratory infections.

In contrast, Dekaban et al. (1972) found that infusions of plasma or whole blood had little effect on patients with Hurler's, Hunter's, and Sanfilippo's diseases, while Moser et al. (1974) found that infusions of HLA-compatible leucocytes in Sanfilippo type B disease produced only a transient increase in GAG catabolism. Undoubtedly the differing degrees of response to this form of enzyme replacement therapy were due in part to differences in activity of the enzyme administered, while the transitory nature of the improvements observed is not surprising in view of the short intracellular half lives of many lysosomal glycosidases and sulphatases (Porter et al., 1971; Hickman and Neufeld, 1972; O'Brien et al., 1973; von Figura and Kresse, 1974). Frequent infusions are therefore required to maintain high levels of enzyme activity and long-term replacement therapy by this method is impracticable.

### Fibroblasts in replacement therapy

The in-vitro studies of Neufeld's group established that normal skin fibroblasts release lysosomal enzymes, which can then be taken up by deficient fibroblasts and restore their capacity to degrade GAG (Fratantoni et al., 1968, 1969; Hickman et al., 1974). When circulating enzyme concentrations are raised by infusions of plasma transient increases in catabolism and excretion of stored GAG ensue (Di Ferrante et al., 1971; Dean et al., 1973, 1975a;...

---

**Table 1** Classification of mucopolysaccharidoses

<table>
<thead>
<tr>
<th>Disease</th>
<th>Deficient enzyme</th>
<th>Storage product</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hurler/Scheie diseases</td>
<td>a-L-Iduronidase</td>
<td>Dermatan, heparan sulphates</td>
</tr>
<tr>
<td>Hunter's disease</td>
<td>a-L-Iduronate-2-sulphate sulphatase</td>
<td>Dermatan, heparan sulphates</td>
</tr>
<tr>
<td>Sanfilippo A disease</td>
<td>Heparan-N-sulphatase</td>
<td>Heparan sulphate</td>
</tr>
<tr>
<td>Sanfilippo B disease</td>
<td>N-Acetyl-a-glucosaminidase</td>
<td>Heparan sulphate</td>
</tr>
<tr>
<td>Morquio's disease</td>
<td>N-Acetylgalactosamine-6-sulphate sulphatase</td>
<td>Keratan sulphate and chondroitin-6-sulphate</td>
</tr>
<tr>
<td>Maroteaux-Lamy disease</td>
<td>N-Acetylgalactosamine-4-sulphate sulphatase (aryl sulphatase B)</td>
<td>Dermatan sulphate</td>
</tr>
<tr>
<td>a-Glucuronidase deficiency</td>
<td>β-Glucuronidase</td>
<td>Dermatan, heparan sulphates</td>
</tr>
</tbody>
</table>

**Fig. 1** Effect of plasma infusion on total 24-h excretion of uronic acid in patient with Sanfilippo's disease. Stippled area represents GAG precipitated by 5-aminoacridine, open areas represent uronic acid containing oligosaccharides of lower molecular weight, and dark horizontal bar indicates days on which plasma was given. (Dean et al., 1973).
Yatziv et al., 1975). Amalgamation of these two sets of data suggests that skin fibroblasts themselves might provide a more continuous source of lysosomal enzymes in vivo and thus increase the rate of catabolism of accumulated GAG over an extended period of time.

This possibility was examined by Dean et al. (1975c), who supplied fibroblasts as a skin allograft in a boy with Hunter's disease and noted a significant increase in excretion of uronic acid, particularly oligosaccharides of lower molecular weight, after grafting. When these oligosaccharides were fractionated by chromatography on Sephadex G-25 the relative proportions of oligosaccharides of lowest molecular weight increased (Fig. 3), while at the same time the sulphate/hexuronic acid molar ratio of the highest molecular weight fraction fell from an abnormally high value of almost 2:1 in preimplantation samples to a normal level of 1:1 in samples taken after treatment. This increased catabolism and desulphation of accumulated oligosaccharides suggested that the circulating level of α-L-idurono-2-sulphate sulphatase (deficient in Hunter's disease) had increased after the grafting. This assumption was confirmed by the increased excretion of 'corrective factor' (which contains α-L-idurono-2-sulphate sulphatase) in the patient's urine. It rose from a level below 1 U/24h to nearly 4 U/24h, and enzyme output and catabolism of accumulated

![Fig. 2](http://jcp.bmj.com) **Effect of plasma infusion on size distribution of oligosaccharides separated from urine of patient with Sanfilippo's disease by gel filtration on Sephadex G-25.** (Dean et al., 1973).

![Fig. 3](http://jcp.bmj.com) **Effect of skin allografts on size distribution of oligosaccharides separated from urine of a patient with Hunter's disease by gel filtration on Sephadex G-25.** Samples taken before grafting designated by negative numbers. (Reproduced from Dean et al. (1975c) by permission of the Editor of Nature (London).
oligosaccharides were both increased more than nine months after grafting.

Transplantation of histocompatible fibroblasts

The promising results produced by skin allografts encouraged transplantation of cultured fibroblasts themselves in three further patients with Hunter’s disease (for details see Dean et al., 1976; Dean et al., 1978). This simplified procedure does not require surgery or general anaesthesia, merely a subcutaneous injection of a suspension of donor cells. Selection of donor cells which are HLA-compatible with those of the patient minimises the risk of rejection and transplanted cells may thus continue to grow and divide, as when cultured in vitro.

The ability of normal skin fibroblasts to synthesise and release all the lysosomal enzymes required for normal GAG catabolism means that all types of mucopolysaccharidosis can be corrected by this procedure, with no need for prior purification of enzymes. Furthermore, the apparent ability of a relatively small increase in intracellular enzyme levels (of the order of 5%) to induce a high degree of correction of GAG catabolism (Bach et al., 1972; O’Brien et al., 1973) suggests that a relatively small number of cells can have a disproportionately large effect.

The effectiveness of fibroblast transplantation was assessed by analysis of urinary GAG and oligosaccharides to determine the effect of donor cells on the rate of catabolism of accumulated dermatan and heparan sulphates. In addition, the appearance of Hunter corrective factor in urine was measured by the method of Cantz et al. (1972) and D-l-idurono-2-sulphate sulphatase activity measured directly in serum and leucocytes using an [3H]-labelled disulphated disaccharide as a substrate (Lim et al., 1974). During this measurement of enzyme activity radioactive monosulphated reaction products were separated from the remaining disulphated substrate by ion-exchange chromatography on columns of ECTEOLA cellulose (Liebaers and Neufeld, 1976).

Changes in excreted GAG after transplantation

There was an immediate increase in total uronic acid excreted by each patient after transplantation, mainly in the form of oligosaccharides of low molecular weight, as would be expected from an increased rate of catabolism of accumulated GAG. Fig. 4 shows data for one of the patients who received fibroblasts (case 1). In addition to the increased excretion of oligosaccharides there was also a small increase in output of GAG. The reason for this is not yet clear.

The Bio-Gel P-2 elution profiles of uronic acid-containing oligosaccharides separated from patients’ urine before transplantation were compared with those obtained from normal children. Although four fractions were resolved from both normal and pathological samples the relative proportions were different, with pathological urines containing considerably more of the larger oligosaccharides (Components I and II, Fig. 5) as well as of the unresolved fraction eluted with the void volume. In samples taken after transplantation the relative proportions of components I and II decreased so that

![Graph](http://jcp.bmj.com/)

**Fig. 4** Effect of transplanted fibroblasts on total 24-h excretion of uronic acid in patient (case 1) with Hunter’s disease. Cross-hatched areas represent GAG precipitated by 5-aminoacidine, open areas uronic acid containing oligosaccharides of lower molecular weight. Samples taken before transplantation designated by negative numbers.

![Graph](http://jcp.bmj.com/)

**Fig. 5** Elution profiles of uronic acid-containing oligosaccharides separated from urine of patient (case 1) with Hunter’s disease by chromatography on Bio-Gel P-2. A profile from a sample taken before transplantation (day 4) and from early and late posttransplantation samples is shown together with that of a normal age matched control sample for comparison. (Reproduced from Dean et al. (1978) by permission of the publishers).
the elution profiles changed to resemble closely those of normal urine (Fig. 5). These changes were again consistent with those expected from increased catabolism of oligosaccharides.

Since the pronounced deficiency of \( \alpha-L \)-iduruno-2-sulphate sulphatase in Hunter's disease leads to a break in catabolism of dermatan and heparan sulphates, leaving a sulphated iduronic acid residue at the non-reducing terminus of accumulated GAG and oligosaccharides, the sulphate:uronic acid molar ratios of the oligosaccharide component I separated by chromatography on Bio-Gel P-2 were determined. Values were abnormally high in all three patients before transplantation, ranging from 1.6:1 to 2.0:1, compared with the normal value of 1.0:1 (see Table 2). After transplantation the sulphate:hexuronic acid ratios decreased to a level at or a little below that of age-matched control samples and remained low throughout the period monitored. In addition to the decrease in sulphate content of fraction I the iduronic acid content of the monosaccharide fraction (fraction IV) estimated by glc was found to be considerably higher in pooled samples analysed after transplantation than in those sampled before treatment (see Table 3). Both of these observations strongly suggest an increase in \( \alpha-L \)-idurono-2-sulphate sulphatase activity subsequent to transplantation, with the removal of sulphate groups from non-reducing terminal iduronic acid groups allowing them in turn to be removed by \( \alpha-L \)-iduronidase, which is not normally deficient in Hunter's disease.

### Changes in Activity of Iduronate Sulphatase

Protein concentrates prepared from patients' urine by precipitation with ammonium sulphate (Dean et al., 1975c) were tested for the presence of Hunter 'corrective factor' (which contains \( \alpha-L \)-idurono-2-sulphate sulphatase) by their ability to correct abnormal \( ^{35}S \)-sulphate incorporation by the patients' own fibroblasts (Cantz et al., 1972). Samples of urine collected before transplantation were almost totally devoid of activity, with mean values < 0.5 U/24 h (Fig. 6). In contrast, samples collected after transplantation were much more active, with mean values ranging from about 3 U/24 h to more than 11 U/24 h for each patient (Table 4), although there was considerable daily fluctuation in output of 'corrective factor'. The results of direct measurement of \( \alpha-L \)-idurono-2-sulphate sulphatase activity in serum and leucocytes of both patients and untreated cases of Hunter's disease are given in Table 5. Twice as much substrate was hydrolysed in 24 h by sera from transplanted patients than from untreated control cases when expressed as DPM/mg serum protein and the leucocyte homogenate had 10 times the activity of an untreated control.

### Discussion

Transplantation of histocompatible normal fibroblasts increased the activity of \( \alpha-L \)-idurono-2-sulphate sulphatase when measured in the urine of all three transplanted patients as corrective factor. This increase in activity was unaffected either by decreasing dosage or total withdrawal of the immunosuppressive drugs given to decrease the risk of rejection. The raised enzyme levels found by direct measurement in the serum and leucocytes of the treated patients were present in blood samples collected at least one year after the end of immunosuppressive therapy and between 1.5 and 3 years after transplantation.

These raised levels of activity seemed to be enough to induce catabolism of a significant proportion of the accumulated dermatan and heparan sulphates, since quantitative analysis showed that excretion of

### Table 2 Sulphate:uronic acid molar ratios of oligosaccharide component I separated on Bio-Gel P-2.

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2·10 (3)</td>
<td>1·15 (5)</td>
<td>1·25 (7)</td>
</tr>
<tr>
<td>2</td>
<td>2·14 (3)</td>
<td>0·54 (7)</td>
<td>0·87 (2)</td>
</tr>
<tr>
<td>3</td>
<td>1·60 (6)</td>
<td>0·95 (7)</td>
<td>0·93 (4)</td>
</tr>
<tr>
<td>Control</td>
<td>1·02</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3 Effect of fibroblast transplantation on proportion of iduronic acid in monosaccharide fraction eluted from Bio-Gel P-2. Iduronic acid content of monosaccharide expressed as percentage of total uronic acid. Group A samples were collected 0-6 weeks before transplantation, group B samples 0-3 months after transplantation, and group C samples 6-16 months after transplantation. Number of samples pooled in each group given in parentheses. Relative amounts of glucuronic and iduronic acids in each group were determined by glc after conversion to trimethylsilyl derivatives, and iduronic acid expressed as a percentage of the total hexuronic acid.

<table>
<thead>
<tr>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>31·9 (5)</td>
<td>45·7 (6)</td>
<td>57·3 (6)</td>
</tr>
</tbody>
</table>
Replacement therapy in the mucopolysaccharidoses

Fig. 6 Effect of transplanted fibroblasts on total 24-h output of 'corrective factor' isolated from urine of patient with Hunter's disease by precipitation with ammonium sulphate. Samples taken before transplantation designated by negative numbers. (Reproduced from Dean et al., 1978 by permission of the publishers).

these GAG, and particularly of the oligosaccharides derived from them, increased after treatment. The abnormal molecular size distribution of oligosaccharides separated by chromatography on Bio-Gel P-2 before treatment changed to a more normal size distribution, the sulphate:uronic acid ratio of oversulphated fractions fell to normal values, and the iduronic acid content of the monosaccharide fraction rose after transplantation. All these changes persisted after the end of immunosuppressive therapy and were again consistent with those expected from increased catabolism of accumulated oligosaccharides.

Both host and donor cells were fully HLA compatible and gave no mixed leucocyte reaction. Because of this the transplanted cells were probably not rejected and continued to produce lysosomal enzymes, including \( \alpha-L-idurono-2\)-sulphate sulphatase, which could then be endocytosed into the lysosomes of host cells. The ability of the respective donor fibroblasts to correct abnormal \(^{35}\)SO\(_4\) metabolism in each of the patient's cells in vitro (Dean et al., 1976, 1978) had been shown before transplantation. Probably this ability may persist after transplantation, since active endocytosis of the appropriate lysosomal enzymes in vitro has been shown by fibroblasts cultured from patients with Sanfilippo's disease and \( \beta\)-glucuronidase deficiency (O'Brien et al., 1973; von Figura and Kresse, 1974; Kaplan et al., 1977). Transfer of lysosomal enzymes from normal donor cells to deficient recipient cells is also known to take place in vivo. For example, lymphocytes from a natural chimeric male calf deficient in \( \alpha\)-mannosidase took up \( \alpha\)-mannosidase from the blood cells of its normal female co-twin at an early stage of fetal development (Jolly et al., 1976). Similarly, \( \beta\)-glucuronidase can be transferred from normal to deficient cells in mosaic tissues of tetraparental mice (Feder, 1976), while heterozygous females with Hunter's disease have two populations of cells, one of which is as deficient in \( \alpha-L-idurono-2\)-sulphate sulphatase as cells from affected patients (Migeon et al., 1977). These heterozygotes do not show symptoms of Hunter's disease, suggesting that transfer of enzymes from normal cells to abnormal ones is a normal event in vivo. Nevertheless, the results we observed in vivo may possibly have been due to a factor released by donor cells that can stimulate host cells themselves to produce a small amount of normal enzyme.

Table 4 Mean 24-hour excretion of Hunter corrective factor before and after transplantation. Values represent mean units of correction (as defined by Barton and Neufeld, 1971) \( \pm \) SE from all samples analysed. Numbers of analyses in parentheses (from Dean et al., 1978, by permission of the publishers).

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Before</th>
<th>After</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.47 ± 0.14 (9)</td>
<td>3.0 ± 0.47 (15)</td>
<td>45.1 (4)</td>
</tr>
<tr>
<td>2</td>
<td>0.45 ± 0.2 (5)</td>
<td>5.8 ± 1.5 (17)</td>
<td>49.0 (4)</td>
</tr>
<tr>
<td>3</td>
<td>0.45 ± 0.2 (5)</td>
<td>11.3 ± 5.1 (14)</td>
<td>59.8 (3)</td>
</tr>
</tbody>
</table>

Table 5 Activity of \( \alpha-L-idurono-2\)-sulphate sulphatase in sera and leucocytes of treated Hunter patients who received fibroblast transplants compared with untreated Hunter patients as controls (from Dean et al., 1978, by permission of the publishers).

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Control Hunter sera</th>
<th>Control Hunter leucocyte activity</th>
<th>Treated Hunter sera</th>
<th>Treated Hunter leucocyte activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Activity (DPM/mg protein)</td>
<td>Mean activity ± SE</td>
<td></td>
<td>Mean activity (DPM/mg protein)</td>
</tr>
<tr>
<td>4</td>
<td>2763</td>
<td></td>
<td></td>
<td>3906</td>
</tr>
<tr>
<td>5</td>
<td>1695</td>
<td>193 ± 298*</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>1408</td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>1706</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3420</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3029</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3318 ± 147*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3505</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30768</td>
</tr>
</tbody>
</table>

Final substrate concentration was 2.0 mmol.

\*P > 0.01, Student's \( t \) test.
The fact that withdrawal of immunosuppressive drugs did not produce a corresponding decrease in \( \alpha \)-L-idurono-2-sulphate sulphatase activity or GAG catabolism suggests that when a good histocompatibility match has been achieved it may not be necessary to suppress the immune response when fibroblasts are transplanted. We do not know how long donor fibroblasts can survive in the host, or indeed whether they can survive, but the presence of increased enzyme activity more than three years after transplantation suggests they can survive for at least this length of time.

The optimum number of cells that should be transplanted is as yet unclear, although in-vitro studies suggest that a relatively small number can have a large effect. For example, O'Brien et al. (1973) showed that as little as 5% of normal intracellular levels of \( \alpha \)-N-acetylgalactosaminidase can induce almost 70% correction of abnormal \(^{35}\)S-sulphate incorporation in cultured fibroblasts from patients with Sanfilippo type B disease, while Kihara et al. (1973) calculated that only 2-5% of normal intracellular levels of arylsulphatase restores normal catabolic function in cells from cases of metachromatic leukodystrophy.

Transplantation of fibroblasts has other important advantages in addition to the long-lived nature of the response. Normal fibroblasts contain all the lysosomal sulphatases and exoglycosidases known to be deficient in each type of mucopolysaccharidosis, and conditioned medium in which normal fibroblasts have been cultured can induce normal catabolism of GAG in each of these types. Probably a similar mechanism can operate in vivo, so that all types of mucopolysaccharidosis can be treated by fibroblast transplantation without prior purification of the necessary deficient enzymes. Moreover, since normal fibroblasts can correct abnormal catabolism in cells derived from patients with lysosomal enzyme deficiencies other than the mucopolysaccharidoses—for example, metachromatic leukodystrophy (Kihara et al., 1973) or \( \alpha \)-mannosidosis (Mersmann et al., 1976)—transplantation of normal fibroblasts may be of value in treating a wide range of other deficiency diseases.

References


Replacement therapy in the mucopolysaccharidoses

emy of Sciences of the United States of America, 64, 360-366.


Replacement therapy in the mucopolysaccharidoses

Michael F. Dean

*J Clin Pathol* 1978 s3-12: 120-127
doi: 10.1136/jcp.s3-12.1.120

Updated information and services can be found at:
http://jcp.bmj.com/content/s3-12/1/120.citation

**Email alerting service**

_These include:_

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/